
MiNK Therapeutics (INKT) Stock Forecast & Price Target
MiNK Therapeutics (INKT) Analyst Ratings
Bulls say
MiNK Therapeutics is rated as a Buy with a price target of $35 based on a discounted cash flow analysis, a 14% discount rate, and a terminal growth rate of 0%. This valuation assumes value for their lead product agenT-797 for gastric cancer with a 20% probability of success, and does not include potential value from other pipeline assets or indications. However, there are risks to achieving this price target, such as safety concerns, lower than expected efficacy, commercial competition, regulatory issues, financing requirements, potential de-listing if share prices fall, and intellectual property protection.
Bears say
MiNK Therapeutics is facing significant risks in achieving their current price target, given the potential for safety concerns or lower efficacy in their clinical programs, as well as potential regulatory hurdles and competition in the market. Additionally, with a lack of inclusion of other pipeline assets or indications in their valuation, there is also a potential for their DCF analysis to be overly optimistic.
This aggregate rating is based on analysts' research of MiNK Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
MiNK Therapeutics (INKT) Analyst Forecast & Price Prediction
Start investing in MiNK Therapeutics (INKT)
Order type
Buy in
Order amount
Est. shares
0 shares